202 related articles for article (PubMed ID: 22996758)
1. Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit.
Morelli A; Comeglio P; Filippi S; Sarchielli E; Vignozzi L; Maneschi E; Cellai I; Gacci M; Lenzi A; Vannelli GB; Maggi M
Prostate; 2013 Mar; 73(4):428-41. PubMed ID: 22996758
[TBL] [Abstract][Full Text] [Related]
2. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS.
Vignozzi L; Gacci M; Cellai I; Morelli A; Maneschi E; Comeglio P; Santi R; Filippi S; Sebastianelli A; Nesi G; Serni S; Carini M; Maggi M
Prostate; 2013 Sep; 73(13):1391-402. PubMed ID: 23765639
[TBL] [Abstract][Full Text] [Related]
3. Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome.
Morelli A; Comeglio P; Filippi S; Sarchielli E; Cellai I; Vignozzi L; Yehiely-Cohen R; Maneschi E; Gacci M; Carini M; Adorini L; Vannelli GB; Maggi M
J Steroid Biochem Mol Biol; 2012 Oct; 132(1-2):80-92. PubMed ID: 22406511
[TBL] [Abstract][Full Text] [Related]
4. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
Giuliano F; Ückert S; Maggi M; Birder L; Kissel J; Viktrup L
Eur Urol; 2013 Mar; 63(3):506-16. PubMed ID: 23018163
[TBL] [Abstract][Full Text] [Related]
5. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome.
Filippi S; Vignozzi L; Morelli A; Chavalmane AK; Sarchielli E; Fibbi B; Saad F; Sandner P; Ruggiano P; Vannelli GB; Mannucci E; Maggi M
J Sex Med; 2009 Dec; 6(12):3274-88. PubMed ID: 19732305
[TBL] [Abstract][Full Text] [Related]
6. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit.
Vignozzi L; Morelli A; Sarchielli E; Comeglio P; Filippi S; Cellai I; Maneschi E; Serni S; Gacci M; Carini M; Piccinni MP; Saad F; Adorini L; Vannelli GB; Maggi M
J Endocrinol; 2012 Jan; 212(1):71-84. PubMed ID: 22010203
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats.
Morelli A; Sarchielli E; Comeglio P; Filippi S; Mancina R; Gacci M; Vignozzi L; Carini M; Vannelli GB; Maggi M
J Sex Med; 2011 Oct; 8(10):2746-60. PubMed ID: 21812935
[TBL] [Abstract][Full Text] [Related]
8. Tadalafil effect on metabolic syndrome-associated bladder alterations: an experimental study in a rabbit model.
Vignozzi L; Filippi S; Comeglio P; Cellai I; Morelli A; Maneschi E; Sarchielli E; Gacci M; Carini M; Vannelli GB; Maggi M
J Sex Med; 2014 May; 11(5):1159-72. PubMed ID: 24612540
[TBL] [Abstract][Full Text] [Related]
9. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.
Andersson KE; de Groat WC; McVary KT; Lue TF; Maggi M; Roehrborn CG; Wyndaele JJ; Melby T; Viktrup L
Neurourol Urodyn; 2011 Mar; 30(3):292-301. PubMed ID: 21284024
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia.
Wang C
Curr Opin Urol; 2010 Jan; 20(1):49-54. PubMed ID: 19887943
[TBL] [Abstract][Full Text] [Related]
11. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Gacci M; Andersson KE; Chapple C; Maggi M; Mirone V; Oelke M; Porst H; Roehrborn C; Stief C; Giuliano F
Eur Urol; 2016 Jul; 70(1):124-133. PubMed ID: 26806655
[TBL] [Abstract][Full Text] [Related]
12. Testosterone treatment improves metabolic syndrome-induced adipose tissue derangements.
Maneschi E; Morelli A; Filippi S; Cellai I; Comeglio P; Mazzanti B; Mello T; Calcagno A; Sarchielli E; Vignozzi L; Saad F; Vettor R; Vannelli GB; Maggi M
J Endocrinol; 2012 Dec; 215(3):347-62. PubMed ID: 23045189
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate.
Zhang W; Zang N; Jiang Y; Chen P; Wang X; Zhang X
Sci Rep; 2015 Dec; 5():17888. PubMed ID: 26657792
[TBL] [Abstract][Full Text] [Related]
14. Effect of a single treatment with tadalafil on blood flow in lower urinary tract tissues in rat models of bladder overdistension/emptying and abdominal aorta clamping/release.
Yoshinaga R; Kawai Y; Oka M; Fuchikami C; Oyama T
Eur J Pharmacol; 2015 May; 754():92-7. PubMed ID: 25697472
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit.
Vignozzi L; Filippi S; Comeglio P; Cellai I; Sarchielli E; Morelli A; Rastrelli G; Maneschi E; Galli A; Vannelli GB; Saad F; Mannucci E; Adorini L; Maggi M
Mol Cell Endocrinol; 2014 Mar; 384(1-2):143-54. PubMed ID: 24486698
[TBL] [Abstract][Full Text] [Related]
16. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract.
Fibbi B; Morelli A; Vignozzi L; Filippi S; Chavalmane A; De Vita G; Marini M; Gacci M; Vannelli GB; Sandner P; Maggi M
J Sex Med; 2010 Jan; 7(1 Pt 1):59-69. PubMed ID: 19796053
[TBL] [Abstract][Full Text] [Related]
17. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
[TBL] [Abstract][Full Text] [Related]
18. Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling.
Zhang X; Zang N; Wei Y; Yin J; Teng R; Seftel A; Disanto ME
Am J Physiol Endocrinol Metab; 2012 Jan; 302(2):E243-53. PubMed ID: 22028410
[TBL] [Abstract][Full Text] [Related]
19. Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia.
Zenzmaier C; Sampson N; Pernkopf D; Plas E; Untergasser G; Berger P
Endocrinology; 2010 Aug; 151(8):3975-84. PubMed ID: 20555034
[TBL] [Abstract][Full Text] [Related]
20. Effects of phosphodiesterase type 5 inhibitor on the contractility of prostate tissues and urethral pressure responses in a rat model of benign prostate hyperplasia.
Kang KK; Kim JM; Yu JY; Ahn BO; Yoo M; Kim YC
Int J Urol; 2007 Oct; 14(10):946-51; discussion 951. PubMed ID: 17880297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
